Psychedelic prodrug from 200+ fungi species gaining policy and market traction
Miller has had misdemeanor drug charges dismissed in Fremont County after authorities cited new information; he has pleaded not guilty to possession of psilocybin mushrooms and his attorney says he did not have drugs on him at the time of arrest. A related active case is cited, with no details released.
Eli Lilly has announced an all-cash deal to acquire AtaiBeckley for up to $2.8 billion upfront, with potential milestone payments. AtaiBeckley’s lead drug, a DMT-related nasal spray for treatment-resistant depression, is in Phase 3, with initial results expected in 2029. The deal signals growing pharma interest in psychedelic therapies amid regulatory momentum.
This week has seen several medical research and regulatory developments: a mid‑stage trial has reported that Insilico Medicine's experimental drug rentosertib altered blood‑protein patterns that aging clocks read as three to four years younger; Stanford teams have published studies implanting human cortical organoids into mice and showing separate developmental origins for hindbrain neurons; and US regulators have named permanent directors for three FDA centers, stabilising leadership after months of upheaval.